Literature DB >> 12084633

The ligand paradox between affinity and efficacy: can you be there and not make a difference?

Terry Kenakin1, Ongun Onaran.   

Abstract

Efficacy is described in terms of the ligand-induced bias of receptor micro-conformations. A virtual simulation of binding of a collection of random ligands can reconcile an apparent paradox in receptor theory, namely the theoretical requirement that affinity and efficacy be related to each other and the experimental fact that medicinal chemistry often can separate structure-activity relationships for affinity and efficacy. The simulation indicates that homoscedacity in the relationship allows for a general correlation with isolated instances of non-compliance. This leads to the conclusion that if a ligand binds to the receptor it will change the receptor by its presence. Therefore, this suggests that all ligands with macro-affinity should be extensively studied for pharmacological activities other than simple G-protein activation with the potential promise of discovering new therapeutic applications for old drugs.

Mesh:

Substances:

Year:  2002        PMID: 12084633     DOI: 10.1016/s0165-6147(02)02036-9

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  27 in total

1.  A signal transduction pathway model prototype I: From agonist to cellular endpoint.

Authors:  Thomas J Lukas
Journal:  Biophys J       Date:  2004-09       Impact factor: 4.033

Review 2.  The mass action equation in pharmacology.

Authors:  Terry Kenakin
Journal:  Br J Clin Pharmacol       Date:  2015-12-21       Impact factor: 4.335

3.  Functional coupling of the human dopamine D2 receptor with G alpha i1, G alpha i2, G alpha i3 and G alpha o G proteins: evidence for agonist regulation of G protein selectivity.

Authors:  Lucien Gazi; Sarah A Nickolls; Philip G Strange
Journal:  Br J Pharmacol       Date:  2003-03       Impact factor: 8.739

4.  New insights into Vitamin D sterol-VDR proteolysis, allostery, structure-function from the perspective of a conformational ensemble model.

Authors:  Mathew T Mizwicki; Craig M Bula; June E Bishop; Anthony W Norman
Journal:  J Steroid Biochem Mol Biol       Date:  2007-03       Impact factor: 4.292

Review 5.  Pharmacological onomastics: what's in a name?

Authors:  T P Kenakin
Journal:  Br J Pharmacol       Date:  2007-08-13       Impact factor: 8.739

Review 6.  Cellular assays as portals to seven-transmembrane receptor-based drug discovery.

Authors:  Terry P Kenakin
Journal:  Nat Rev Drug Discov       Date:  2009-07-17       Impact factor: 84.694

7.  Translating biased signaling in the ghrelin receptor system into differential in vivo functions.

Authors:  Franziska Mende; Cecilie Hundahl; Bianca Plouffe; Louise Julie Skov; Bjørn Sivertsen; Andreas Nygaard Madsen; Michael Lückmann; Thi Ai Diep; Stefan Offermanns; Thomas Michael Frimurer; Michel Bouvier; Birgitte Holst
Journal:  Proc Natl Acad Sci U S A       Date:  2018-10-09       Impact factor: 11.205

8.  Molecular structure of the rabbit alpha2A-adrenoceptor: a contribution to the alpha2A-adrenoceptor versus I1 imidazoline receptor controversy.

Authors:  M Brüss; H Bönisch; M Göthert; G J Molderings
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-02-14       Impact factor: 3.000

9.  A different molecular interaction of bradykinin and the synthetic agonist FR190997 with the human B2 receptor: evidence from mutational analysis.

Authors:  Francesca Bellucci; Stefania Meini; Paola Cucchi; Claudio Catalani; Wolfgang Reichert; Sabrina Zappitelli; Luigi Rotondaro; Laura Quartara; Alessandro Giolitti; Carlo Alberto Maggi
Journal:  Br J Pharmacol       Date:  2003-08-26       Impact factor: 8.739

10.  Allosteric theory: taking therapeutic advantage of the malleable nature of GPCRs.

Authors:  Terry Kenakin
Journal:  Curr Neuropharmacol       Date:  2007-09       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.